Clinical importance of hepatic cytochrome P450 in drug metabolism.
about
The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteersSummary of information on human CYP enzymes: human P450 metabolism data.Review article: pharmacokinetic concerns in the selection of anti-ulcer therapy.Drug interactions and the statins.Drug interactions of the newer oral antifungal agents.Pharmacogenetics and psychopharmacotherapy.The importance of drug interactions in epilepsy therapy.A clinical study investigating the pharmacokinetic interaction between NN703 (tabimorelin), a potential inhibitor of CYP3A4 activity, and midazolam, a CYP3A4 substrate.Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors.Examination of metabolic pathways and identification of human liver cytochrome P450 isozymes responsible for the metabolism of barnidipine, a calcium channel blocker.Ziprasidone and the activity of cytochrome P450 2D6 in healthy extensive metabolizers.Steroid biotransformations in biphasic systems with Yarrowia lipolytica expressing human liver cytochrome P450 genes.Hepatocyte cell lines: their use, scope and limitations in drug metabolism studies.Determination of the new MDR-modifier PFP 6 and its metabolites in human liver microsomes by high-performance liquid chromatography.Impact of physiological, physicochemical and biopharmaceutical factors in absorption and metabolism mechanisms on the drug oral bioavailability of rats and humans.A Comparison of the In Vitro Inhibitory Effects of Thelephoric Acid and SKF-525A on Human Cytochrome P450 Activity.Bio-sample preparation and analytical methods for the determination of tricyclic antidepressants.Specific safety and tolerability considerations in the use of anticonvulsant medications in children.Psychophysiological stress: a significant parameter in drug pharmacokinetics.Pharmacokinetic and pharmacodynamic drug interactions between antiretrovirals and oral contraceptives.Identification of benzazole compounds that induce HIV-1 transcription.Approach to the prediction of the contribution of major cytochrome P450 enzymes to drug metabolism in the early drug-discovery stage.Biooxidation of Ciguatoxins Leads to Species-Specific Toxin Profiles.Regulation of cytochromes P450 during inflammation and infection.Hepatotoxicity in rats treated with dimethylformamide or toluene or both.Oral terbinafine in the treatment of onychomycosis: a comparison of continuous and extended-pause regimens.Evaluation of dextromethorphan N-demethylation activity as a biomarker for cytochrome P450 3A activity in man.Ones, thiones, and N-oxides: an exercise in imidazole chemistry.Studies on the inhibition of human cytochromes P450 by selenocysteine Se-conjugates.Human constitutive androstane receptor mediates induction of CYP2B6 gene expression by phenytoin.The effect of aprepitant and race on the pharmacokinetics of cyclophosphamide in breast cancer patients.Relative roles of CYP2C19 and CYP3A4/5 in midazolam 1'-hydroxylation.Enzymatic characteristics of CYP3A5 and CYP3A4: a comparison of in vitro kinetic and drug-drug interaction patterns.Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans.Effects of propofol on human hepatic microsomal cytochrome P450 activities.Pharmacokinetics of midazolam in Vietnamese subjects.Activation of phenacetin O-deethylase activity by alpha-naphthoflavone in human liver microsomes.Stress is a critical player in CYP3A, CYP2C, and CYP2D regulation: role of adrenergic receptor signaling pathways.
P2860
Q24564995-30795329-3F16-428C-AFE3-6230DAD4A349Q32103802-73CD233E-44F9-483A-B3F2-EBDB79706C31Q33771058-6C92D83E-E506-44FE-860F-F19061DFBF4CQ33786019-C9AE8280-D2BA-4AFA-B76B-B0F515F00EEFQ33871614-D731EE08-CAA4-4FE2-A32C-33C8314F201BQ33962212-C665E4FC-5795-401C-9E01-1093DBF13CE3Q34123652-B565F857-1FF2-4BF6-AB61-A996E2C5E9BEQ34180397-A45B565F-8D86-4C9D-B1E6-C9255596EC8FQ34429206-BBD3900B-20F7-45D0-9ED8-0F712C2BC8EDQ34743662-FAE0831B-76CC-49C4-9B25-C411606682E9Q36055505-4DF24F1F-6D2C-460A-9806-17E9853858B9Q36531595-51FE223A-1873-4701-B586-575B113F7764Q36546250-BE4DD51E-A4F1-4597-89EA-6FC33D96DC3DQ36818020-618B80AD-EDC9-4266-97B0-B69826B591B8Q36909306-69FB3436-29C6-484A-A6D5-86974B9E1B8DQ37684203-DEC169ED-D372-4831-9DA4-E536F7BAD38DQ37822787-651A6E9B-4C33-4243-80CA-F935972C1C82Q38026034-9BBCE91A-ABE8-493D-832F-2C978CE4B767Q38120048-B35E3F3C-4F34-41A1-B4F0-03380FB1AA30Q38261574-4FF95085-89A2-42E5-9D8C-C602877589D8Q40154908-37322D3A-951C-48A0-8EAC-369AA26EEAB1Q40300462-FB231527-5BB7-48F0-9282-6F70EE123A95Q41175015-08C55C23-B90E-4CC4-B029-134EFE083C77Q41676809-7ED723BD-71CE-4935-9CDB-F474F3A59682Q41845512-49CAA820-FC33-45D8-9CC9-E057D95100CBQ43543207-90FDEE7A-016E-4008-A787-A4D8EE36EA9EQ44032657-64D1244C-3DF4-485E-ACBF-0133B97E63DAQ44119932-61D239FA-C27B-42F7-80B4-92180B8CE125Q44273087-81A7783D-D68D-4002-8BF8-2DF7C028DF48Q44881276-9D2251C1-0109-4318-882A-54285FBA2D55Q46608510-604967D6-2520-4AA7-9662-0E058148C00BQ48585391-52FC3132-387E-4A9F-B540-3AEFCFDB7612Q48698266-3ACEC11F-4A07-4416-8707-1D39DDB5F117Q51482811-30DA617E-F9A0-4155-A438-4A6F06090867Q51499258-AD644F07-5A78-488D-9E20-48F8FB335E08Q51555435-5D9253A4-63BD-4ABA-BB52-8CEBFE70FE35Q52574048-EF28D669-AA5A-4BF2-972F-72A02951C563Q54516740-70421A55-C782-492F-8730-ED59A0D3D6A4
P2860
Clinical importance of hepatic cytochrome P450 in drug metabolism.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Clinical importance of hepatic cytochrome P450 in drug metabolism.
@en
type
label
Clinical importance of hepatic cytochrome P450 in drug metabolism.
@en
prefLabel
Clinical importance of hepatic cytochrome P450 in drug metabolism.
@en
P2860
P1476
Clinical importance of hepatic cytochrome P450 in drug metabolism.
@en
P2093
Spatzenegger M
P2860
P304
P356
10.3109/03602539508998329
P407
P577
1995-01-01T00:00:00Z